Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rockwell Medical, Inc. (DE) Common Stock

RMTI

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $6.61 – $7.02
Volume 24,166
Market cap $27M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$26.85M
Price / earnings
—
Price / book
0.81×
Price / sales
0.37×
EV / sales
0.35×
EV / EBITDA
-11.6×

Profitability

Earnings per share
-$1.46
Return on assets
-10.18%
Return on equity
-17.53%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.29×
Current ratio
2.47×
Quick ratio
2.27×
Cash ratio
0.71×

Cash flow

Price / cash flow
10.03×
Price / free cash flow
32.43×
Free cash flow
$828K

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RMTI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$19.12M$17.78M$17.34M$18.35M$15.93M$16.07M$18.91M$24.67M
Cost of revenue$16.01M$14.54M$14.44M$14.47M$13.66M$13.57M$15.87M$21.03M
Gross profit$3.11M$3.24M$2.9M$3.88M$2.27M$2.5M$3.04M$3.63M
Selling, general and administrative$4.37M$4.26M$4.38M$4.28M$3.86M$3.85M$4.4M$4.15M
Research and development$114K$40K$0$0$0$0$0$1K
Total operating expenses$5.33M$4.3M$4.38M$4.28M$3.86M$3.85M$4.4M$4.15M
Operating income-$2.22M-$1.06M-$1.48M-$398K-$1.58M-$1.35M-$1.36M-$519K
Interest expense-$282K-$281K-$282K-$286K-$285K-$276K-$277K-$289K
Income before taxes-$2.32M-$1.17M-$1.61M-$554K-$1.75M-$1.49M-$1.52M-$756K
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.32M-$1.17M-$1.61M-$554K-$1.75M-$1.49M-$1.52M-$756K
Net income attributable to common shareholders-$2.32M-$1.33M-$1.61M-$554K-$1.75M-$1.65M-$1.52M-$756K
EBITDA-$824K-$569K-$969K$148K-$1.04M-$786K-$821K$24K
Basic earnings per share-$0.59-$0.34-$0.40-$0.14-$0.49-$0.48-$0.40-$0.23
Diluted earnings per share-$0.59-$0.34-$0.40-$0.14-$0.49-$0.48-$0.40-$0.25

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Rockwell Medical (RMTI) Reports Q3 Loss, Tops Revenue Estimates

Rockwell Medical reported a quarterly loss of $0.59 per share, significantly worse than the consensus estimate of $0.18, representing a -227.78% earnings surprise. The company posted revenues of $19.12 million, slightly beating estimates but has underperformed the S&P 500 by 26.4% year-to-date. With a Zacks Rank #3 (Hold) rating and the Medical-Products industry in the bottom 42% of performance, the stock is expected to perform in line with the market.

Zacks Investment Research

Curaleaf Holdings, Inc. (CURLF) Reports Q3 Loss, Beats Revenue Estimates

Curaleaf Holdings reported a Q3 loss of $0.14 per share, beating the consensus estimate of $0.16 loss, with a 12.50% earnings surprise. Revenue reached $352.65 million, surpassing estimates by 1.79% and up from $320.24 million year-over-year. The stock has gained 21.2% year-to-date, outperforming the S&P 500's 10.2% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, and operates in the Medical-Products industry which ranks in the bottom 35% of Zacks industries.

The Motley Fool

Rockwell Medical Tops Q2 EPS View

Rockwell Medical reported Q2 2025 earnings with a 37.8% revenue decline due to losing its largest customer, but signed four new multi-year supply agreements and maintained tight cost controls.

Benzinga

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

DaVita's stock has gained 47.3% year-to-date, outperforming the industry and the S&P 500. The rally is attributed to the company's strong dialysis and lab services, solid Q2 2024 performance, and expansion through acquisitions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 1, 20261-for-10reverse split
May 13, 20221-for-11reverse split